Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04) with a linear range of 0.06-4 ng/mL (QC tested).
Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04) (Cat. No. MME-MY2210) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 100% Human Serum and then add Biotinylated Human Her2, His,Avitag, premium grade at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (QC tested).
Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04) at 5 μg/mL, add Disitamab Vedotin (RC48) and then add Biotinylated Human Her2, His,Avitag, premium grade at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Routinely tested).
ELISA binding of Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb used at 1:10000 concentration.
Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1G04) is specific to Disitamab Vedotin (RC48) and Trastuzumab MMAE, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
